Shanghai Tellgen Life Science

Shanghai Tellgen Life Science

Shanghai Tellgen Life Science was established in 2003 by Yao Jianlong, who serves as Chairman and General Manager. The company is headquartered in Shanghai's Zhangjiang Hi-Tech Park and went public on the Shenzhen Stock Exchange in 2017. Tellgen operates as an operating company first, developing in-vitro diagnostic reagents and instruments, while selectively backing early-stage healthcare ventures through a corporate investment function. The firm's investment posture centers on venture-stage opportunities in China's healthcare, biotechnology, and advanced-materials sectors. Tellgen's commercial diagnostics menu spans tumor markers, HPV genotyping, DNA methylation assays, ToRCH panels, and a full biochemical reagent line — all manufactured in-house. This operating footprint gives the corporate venture arm direct visibility into clinical demand. Instrument platforms include the TESMI series of chemiluminescence analyzers, the F4000 flow-fluorescence system, and the Luminex-200 multiplexing unit. The diagnostics business holds roughly 300 registrations, covering class-III oncological and infectious-disease kits alongside class-I and class-II reagents. The firm deploys capital from its balance sheet, though deployment totals are undisclosed. Yao Jianlong's internal circle includes Zhou Ai Guo, a Director and Deputy General Manager who also holds a role at Shanghai Fudan-Zhangjiang Bio-Pharmaceutical. An independent-director tie to WuXi AppTec via Dr. Wei Yu provides additional life-science network depth. The company disclosed involvement with the Beijing Aipu Cancer Patient Care Foundation, indicating a philanthropic presence alongside the corporate and investment activities. Tellgen's structural distinction lies in the tight coupling of an active diagnostics manufacturer with a corporate venture function. The same entity that produces HPV-27 genotyping kits and the fast-line T9 integrated analyzer makes venture bets on China-based healthcare startups. This arrangement creates a feedback loop unavailable to pure financial investors: product revenue funds investment activity, while portfolio companies can serve as technology scouts or eventual acquisition targets.